We used two methods based on a biological data-driven system for predicting HIV-1 drug susceptibility from a viral genotype (the Vircow TYPE HIV-1 test and the Stanford HIVdb) and a third method based on an in vitro phenotypic resistance assay that measures the level of resistance of recombinant HIV-1 from plasma samples (Antivirogramw).
The two drugs evaluated were tipranavir and darunavir, as these were the agents administered in the patients’ new regimen. Correlation coefficients (Spearman’s r) and the P value (two-tailed) were calculated using GraphPad Prism v5.0 software